These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29347916)

  • 1. Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models.
    Sanghera S; Coast J; Martin RM; Donovan JL; Mohiuddin S
    BMC Cancer; 2018 Jan; 18(1):84. PubMed ID: 29347916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
    Callender T; Emberton M; Morris S; Eeles R; Kote-Jarai Z; Pharoah PDP; Pashayan N
    PLoS Med; 2019 Dec; 16(12):e1002998. PubMed ID: 31860675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
    Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project.
    Lord J; Willis S; Eatock J; Tappenden P; Trapero-Bertran M; Miners A; Crossan C; Westby M; Anagnostou A; Taylor S; Mavranezouli I; Wonderling D; Alderson P; Ruiz F
    Health Technol Assess; 2013 Dec; 17(58):v-vi, 1-192. PubMed ID: 24325843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.
    Keeney E; Sanghera S; Martin RM; Gulati R; Wiklund F; Walsh EI; Donovan JL; Hamdy F; Neal DE; Lane JA; Turner EL; Thom H; Clements MS
    Pharmacoeconomics; 2022 Dec; 40(12):1207-1220. PubMed ID: 36201131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for prostate cancer.
    Ilic D; Neuberger MM; Djulbegovic M; Dahm P
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation.
    Hummel S; Simpson EL; Hemingway P; Stevenson MD; Rees A
    Health Technol Assess; 2010 Oct; 14(47):1-108, iii-iv. PubMed ID: 21029717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
    Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
    J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy.
    Campbell F; Thokala P; Uttley LC; Sutton A; Sutton AJ; Al-Mohammad A; Thomas SM
    Health Technol Assess; 2014 Sep; 18(59):1-120. PubMed ID: 25265259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation.
    Mowatt G; Scotland G; Boachie C; Cruickshank M; Ford JA; Fraser C; Kurban L; Lam TB; Padhani AR; Royle J; Scheenen TW; Tassie E
    Health Technol Assess; 2013 May; 17(20):vii-xix, 1-281. PubMed ID: 23697373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation.
    Ramsay CR; Adewuyi TE; Gray J; Hislop J; Shirley MD; Jayakody S; MacLennan G; Fraser C; MacLennan S; Brazzelli M; N'Dow J; Pickard R; Robertson C; Rothnie K; Rushton SP; Vale L; Lam TB
    Health Technol Assess; 2015 Jul; 19(49):1-490. PubMed ID: 26140518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of prostate cancer screening using the Stockholm3 test.
    Karlsson AA; Hao S; Jauhiainen A; Elfström KM; Egevad L; Nordström T; Heintz E; Clements MS
    PLoS One; 2021; 16(2):e0246674. PubMed ID: 33630863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: A micro-simulation study of 230 scenarios.
    Getaneh AM; Heijnsdijk EAM; Roobol MJ; de Koning HJ
    Cancer Med; 2020 Oct; 9(20):7742-7750. PubMed ID: 32813910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men.
    Teoh JY; Leung CH; Wang MH; Chiu PK; Yee CH; Ng CF; Wong MC
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):615-621. PubMed ID: 32606435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.
    Heijnsdijk EA; Denham D; de Koning HJ
    Value Health; 2016; 19(2):153-7. PubMed ID: 27021748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study.
    Leal J; Welton NJ; Martin RM; Donovan J; Hamdy F; Neal D; Noble S; Lane A; Wolstenholme J
    Cancer Epidemiol; 2018 Feb; 52():99-105. PubMed ID: 29278842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
    Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
    PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
    Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
    Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.
    Pataky R; Gulati R; Etzioni R; Black P; Chi KN; Coldman AJ; Pickles T; Tyldesley S; Peacock S
    Int J Cancer; 2014 Aug; 135(4):939-47. PubMed ID: 24443367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.